CLINICAL TRIAL: PHASE II SAFETY AND IMMUNOGENICITY STUDY OF QUADRIVALENT HUMAN P

临床试验：四价人 P 的 II 期安全性和免疫原性研究

• 批准号: 7950822
• 负责人: Sharon A Nachman
• 金额: $ 0.21万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950822
• 关键词: Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Human; Human Papillomavirus; Human papillomavirus 6; Institution; Laboratory Research; Phase; Placebos; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; Vaccines; Virus-like particle; immunogenicity

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being done to evaluate the safety and effect of an investigational vaccine against human papilloma virus (HPV). The investigational vaccine is called Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-Like Particle [VLP] Vaccine (QHPV Vaccine, also known as GARDASIL¿¿). Both the vaccine and placebo used in this study will be provided by Merck Research Laboratories. The study will look at two things.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以出现在其他 CRISP 条目中 列出的机构是。 中心，不一定是研究者的机构。 本研究旨在评估针对人乳头瘤病毒 (HPV) 的研究疫苗的安全性和效果。该研究疫苗称为人乳头瘤病毒（6、11、16、18 型）L1 病毒样颗粒 [VLP] 疫苗（ QHPV 疫苗，也称为 GARDASIL¿）。本研究中使用的疫苗和安慰剂均由默克研究实验室提供。在两件事上。